ABT-894 is being developed under a licensing agreement with Abbott as a new treatment of ADHD. A Phase II study in adults with ADHD has demonstrated positive results and Abbott is now preparing the compound with a view to conducting a Phase II study also in children with ADHD.
ABT-894 is an α4β2 subtype-specific nicotinic receptor agonist, which was identified under an earlier drug discovery collaboration between NeuroSearch and Abbott within the field of neuronal nicotinic receptors. Under the terms of the license agreement, Abbott is responsible for and finances all clinical development, production and marketing, and NeuroSearch is eligible to receive milestone payments and royalties on Abbott’s global sales of ABT-894.
